Is the Patent Office Forcing Race into Biotechnology Patents?
By Jonathan Kahn, Biopolitical Times guest contributor | 06. 14. 2011
A review of recent patent applications to the United States Patent and Trademark Office (PTO) has uncovered a highly problematic new practice: PTO examiners are requiring applicants to include racial categories in the claims sections of some biotechnology patent submissions, where they provide the basis for subsequent research, development, and marketing of products developed from the patent.
In a recent article in Nature Biotechnology, I explore the general contours of this phenomenon, which first came to light in a December 2008 presentation by PTO Quality Assurance Specialist Kathleen Bragdon titled “A Look at Personalized Medicine.” Taking an example of a treatment for breast cancer, the presentation argued that in cases where effectiveness for all races was not established, “a scope of enablement rejection must be considered.” In other words, the patent could cover only those racial groups that had been included in the underlying study. The implication was that race must be considered a genetically salient factor in biotechnology patent applications.
The critical responses Bragdon’s presentation prompted could have led the PTO to reconsider the relevance...
Related Articles
From the thirteenth floor of a glass tower at the Oregon Health & Science University, you get a panoramic view of downtown Portland and the majestic mountains in the distance. But it's what's happening inside the building that's brought me...
New York-based fertility doctor John Zhang is finally facing censure for conducting an unapproved, controversial procedure in US and Mexican fertility clinics last year, demonstrating a growing rift between scientists willing to “go rogue” and those committed to playing by the rules.
As Zhang and his co-authors describe in an April Reproductive BioMedicine Online article, they used a technique known as 3-person IVF to genetically modify human embryos in New York, exported them to Mexico for transplantation, and delivered...
As the scientific community takes in the work of the team who edited the DNA of the human embryos this month, different opinions about the safety, efficacy, and potential of the technique abound.
THE GENE EDITING PROCESS
In a lab...
By Antonio Regalado, MIT Technology Review | 08.07.2017
Scientists are trying to manufacture eggs and sperm in the laboratory. Will it end reproduction as we know it?
Let’s call him B.D., because that’s what his wife does on her infertility blog, Shooting Blanks. Several years ago, the 36-year-old...
